ClinicalTrials.gg
CompletedNCT00384085Updated May 6, 2011Results posted

Insulin Glargine "All to Target" Trial

A Phase 4 interventional study of Insulin Glulisine and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-06.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
Largest of 25
588 · median 281
Started
2006
with 1 other
Phase 4
14 of 26
none open now
Registered
11th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The primary objectives were:

  • To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic control (as measured by hemoglobin A1c [HbA1c] \<7.0%) at Week 60
  • To demonstrate the noninferiority of Lantus plus addition of 1 mealtime Apidra injection (Lantus/Apidra-1) versus twice-daily Premixed insulin based on the reduction from Baseline to Week 60 in HbA1c
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Male or female patients
  • 30 to 80 years of age
  • \<45 kg/m2
  • With Type 2 diabetes mellitus for at least 2 years
  • With an level at screening of >7.5% and >7.0% at randomization
  • On stable dual or triple oral therapy for at least 3 months
  • Oral agents in 2 or 3 of the following classes: SU or repaglinide, biguanide, or TZD, willing and able to perform self-monitoring of BG
  • Females of child-bearing potentially were required to be willing and able to use adequate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
588 participants (actual)

Study arms

  • Experimental
    Lantus/Apidra-3

    Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.

    Drug: Insulin Glargine · Drug: Insulin Glulisine

  • Experimental
    Lantus/Apidra-1

    Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.

    Drug: Insulin Glulisine · Drug: Insulin Glargine

  • Experimental
    Novolog Mix 70/30

    Premixed insulin (Novolog® Mix 70/30) added to oral agents.

    Drug: Premixed Insulin

Interventions

  • Subcutaneous injection up to 1 injection per day

    Also known as: Apidra

  • Subcutaneous injection once-a-day

    Also known as: Lantus

  • DrugPremixed Insulin

    Subcutaneous injection twice-a-day.

    Also known as: Novolog Mix 70/30

  • Subcutaneous injection up to 3 injections per day.

    Also known as: Apidra

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)

    Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.

    Time frame: At week 60

  2. Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population

    Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.

    Time frame: At week 60

  3. Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)

    Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.

    Time frame: At week 60

Secondary outcomes

  1. Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)

    Absolute Change in HbA1c from Baseline to Week 60.

    Time frame: From baseline to week 60

  2. Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)

    Patients who achieved an HbA1c value \<7.0% were defined as responders. Patients who did not achieve HbA1c values \<7.0% and patients with missing HbA1c values were considered nonresponders.

    Time frame: At week 60

  3. Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) <50 mg/dl

    Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration. A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of \<50 mg/dL with reported symptoms.

    Time frame: At week 60

  4. Adjusted Incidence Rate of Hypoglycemia

    Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia. A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) \<36 mg/dL during or soon after the event. A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion. Nocturnal = events occurring between 00:00 \& 06:00 based on a 24-hour clock. An event is included if the HE start date is within the treatment period.

    Time frame: Week 60

  5. Adjusted Hypoglycemic Event Rates (Event/Patient-year)

    Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study. An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to \& including 1 day after the date of last dose of study drug).

    Time frame: Week 60

07

Results

Posted Apr 26, 2011

Participant flow

A total of 123 study sites were activated in the United States; 99 sites enrolled and randomized 588 patients from May 2006 to March 2010. 582 patients out of 588 patients were treated. Three sites (which included 26 patients) were found to be non Good Clinical Practices (GCP) compliant.

Participant flow — Overall Study
MilestoneLantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30
Started195196197
Intent-to-treat (itt)195196197
Treated (safety population)194194194
Intent-to-treat (excluding nongcp sites)187186189
Completed156150141
Not completed394656
Withdrew: Adverse event554
Withdrew: Lack of efficacy032
Withdrew: No longer requires study treatment101
Withdrew: Protocol violation222
Withdrew: Lost to follow-up9910
Withdrew: Progressive disease010
Withdrew: Withdrawal by subject141929
Withdrew: Patient non-compliant445
Withdrew: Physician decision100
Withdrew: Loss of site personnel101
Withdrew: Sponsor decision121
Withdrew: Patient moved101
Withdrew: Patient required surgery010

Outcome measures

PrimaryPercentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)

Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.

Time frame:
At week 60
Reported as:
Number · percentage of participants
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)
percentage of participantsLantus/Apidra-3Novolog Mix 70/30
HbA1c < 7.0%43.338.6
HbA1c ≥ 7.0%35.332.3
Missing data21.429.1
Statistical analysis
  • Lantus/Apidra-3 vs Novolog Mix 70/30 · Regression, Logistic · p = 0.0628 (The type I error was controlled by performing a 2-tailed comparison at a p=0.0475 level for superiority testing.) · Adjusted odds ratio: 1.56 · 95% CI 0.97 to 2.52
PrimaryChange From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population

Absolute Change in HbA1c from Baseline to Week 60. If the Week 60 HbA1c evaluation was missing, the patient was counted as having not completed per protocol.

Time frame:
At week 60
Reported as:
Least squares mean · percent HbA1c
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)Per Protocol Population
percent HbA1cLantus/Apidra-1Novolog Mix 70/30
baseline HbA1c9.30 ± 0.1769.06 ± 0.187
Absolute change in HbA1c from baseline-2.30 ± 0.126-1.97 ± 0.132
Statistical analysis
  • Lantus/Apidra-1 vs Novolog Mix 70/30 · Mixed Models Analysis · p = 0.0359 (The type I error was controlled by performing a 2-tailed comparison at a p=0.0025 level for noninferiority testing.) · Adjusted mean of difference: -0.34 · 95% CI -0.82 to 0.15
PrimaryPercentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)

Responders defined as patients who achieved an HbA1c value \<7.0% versus nonresponders. Patients who did not achieve an HbA1c value \<7.0% and patients with a missing HbA1c value at Week 60 were considered to be nonresponders.

Time frame:
At week 60
Reported as:
Number · percentage of participants
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - ITT Population With All Sites) (Sensitivity Analysis)
percentage of participantsLantus/Apidra-3Novolog Mix 70/30
HbA1c < 7.0%44.138.1
HbA1c ≥ 7.0%34.432.0
Missing data21.529.9
Statistical analysis
  • Lantus/Apidra-3 vs Novolog Mix 70/30 · Regression, Logistic · p = 0.0313 (The type I error was controlled by performing a 2-tailed comparison at a p=0.0475 level for superiority testing.) · Adjusted odds ratio: 1.66 · 95% CI 1.04 to 2.64
SecondaryAbsolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)

Absolute Change in HbA1c from Baseline to Week 60.

Time frame:
From baseline to week 60
Reported as:
Least squares mean · percent HbA1c
Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)
percent HbA1cLantus/Apidra-3Novolog Mix 70/30
Absolute Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30)-2.45 ± 0.134-2.13 ± 0.142
Statistical analysis
  • Lantus/Apidra-3 vs Novolog Mix 70/30 · ANCOVA · p = 0.0565 · Adjusted mean of difference: -0.31 · 95% CI -0.63 to 0.01
SecondaryPercentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)

Patients who achieved an HbA1c value \<7.0% were defined as responders. Patients who did not achieve HbA1c values \<7.0% and patients with missing HbA1c values were considered nonresponders.

Time frame:
At week 60
Reported as:
Number · percentage of participants
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)
percentage of participantsLantus/Apidra-1Novolog Mix 70/30
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 (Lantus/Apidra-1 Versus Novolog Mix 70/30)51.139.5
Statistical analysis
  • Lantus/Apidra-1 vs Novolog Mix 70/30 · Regression, Logistic · p = 0.0140 · Adjusted odds ratio: 1.79 · 95% CI 1.12 to 2.85
SecondaryPercentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) <50 mg/dl

Severe hypoglycemia was defined as an event with clinical symptoms that are considered to result from hypoglycemia in which the patient required assistance of another person and one of the following: the event was associated with a measured blood glucose level below 36 mg/dL or the event was associated with prompt recovery after oral carbohydrate, iv glucose, or glucagon administration. A symptomatic hypoglycemic event was defined as a hypoglycemic episode with an associated SMBG value of \<50 mg/dL with reported symptoms.

Time frame:
At week 60
Reported as:
Number · percentage of participants
Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) <7.0% at Week 60 Without a Severe Hypoglycemic Event or a Symptomatic Hypoglycemic Event With an Self Monitoring Blood Glucose (SMBG) <50 mg/dl
percentage of participantsLantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30
HbA1c < 7.0%23.025.014.1
HbA1c ≥ 7.0%55.752.258.4
Missing data21.322.827.6
Statistical analysis
  • Lantus/Apidra-3 vs Lantus/Apidra-1 · Regression, Logistic · p = 0.9268 · Adjusted odds ratio: 1.02 · 95% CI 0.61 to 1.71
  • Lantus/Apidra-3 vs Novolog Mix 70/30 · Regression, Logistic · p = 0.0107 · Adjusted odds ratio: 2.11 · 95% CI 1.19 to 3.73
  • Lantus/Apidra-1 vs Novolog Mix 70/30 · Regression, Logistic · p = 0.0121 · Adjusted odds ratio: 2.06 · 95% CI 1.17 to 3.61
SecondaryAdjusted Incidence Rate of Hypoglycemia

Adjusted incidence rate of hypoglycemia: estimated percent of patients having at least 1 event of a given type of hypoglycemia. A severe Hypoglycemic Event (HE) is one where patient requires assistance. It is confirmed either by a prompt response to certain countermeasures or by a blood Glucose (BG) \<36 mg/dL during or soon after the event. A serious HE is one where the patient has loss of consciousness, coma, seizure, or convulsion. Nocturnal = events occurring between 00:00 \& 06:00 based on a 24-hour clock. An event is included if the HE start date is within the treatment period.

Time frame:
Week 60
Reported as:
Mean · estimated percentage per patient
Adjusted Incidence Rate of Hypoglycemia
estimated percentage per patientLantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30
Self-Monitored Blood Glucose (SMBG) < 70 mg/dl74.40 ± 3.8374.78 ± 3.8083.15 ± 3.11
SMBG< 70 mg/dl with symptoms60.14 ± 4.2462.50 ± 4.1871.98 ± 3.76
SMBG< 70 mg/dl, nocturnal46.30 ± 4.2840.31 ± 4.1842.53 ± 4.19
SMBG< 70 mg/dl with symptoms, nocturnal37.03 ± 4.1033.55 ± 3.9835.68 ± 4.03
SMBG< 50 mg/dl39.77 ± 4.2739.55 ± 4.2553.14 ± 4.33
SMBG< 50 mg/dl with symptoms31.51 ± 3.9532.56 ± 4.0045.92 ± 4.30
SMBG< 50 mg/dl, nocturnal12.05 ± 2.8811.29 ± 2.7812.58 ± 2.96
SMBG< 50 mg/dl with symptoms, nocturnal6.93 ± 2.287.49 ± 2.438.88 ± 2.76
SMBG< 36 mg/dl10.89 ± 2.238.63 ± 2.0214.32 ± 2.52
Severe hypoglycemias10.10 ± 2.177.19 ± 1.858.23 ± 1.97
Serious hypoglycemias0.41 ± 0.430.00 ± 0.002.29 ± 1.12
SecondaryAdjusted Hypoglycemic Event Rates (Event/Patient-year)

Adjusted Hypoglycemic event rate: Total # of events for a given type of hypoglycemia divided by the total exposure to study drug (patient-years). Rates are estimated from a general linear model adjusted for baseline BMI and oral agent combination of antidiabetic medications on which the patient entered the study. An event is included if the hypoglycemic event start date is within the treatment period (i.e., from the Randomization date to \& including 1 day after the date of last dose of study drug).

Time frame:
Week 60
Reported as:
Mean · event per patient year
Adjusted Hypoglycemic Event Rates (Event/Patient-year)
event per patient yearLantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30
Self-Monitored Blood Glucose (SMBG) < 70 mg/dl14.50 ± 1.7212.85 ± 1.5020.42 ± 2.38
SMBG< 70 mg/dl with symptoms7.23 ± 0.997.11 ± 0.9912.23 ± 1.68
SMBG< 70 mg/dl, nocturnal1.90 ± 0.321.84 ± 0.311.68 ± 0.29
SMBG< 70 mg/dl with symptoms, nocturnal1.16 ± 0.211.10 ± 0.211.16 ± 0.23
SMBG< 50 mg/dl1.38 ± 0.211.17 ± 0.192.42 ± 0.36
SMBG< 50 mg/dl with symptoms0.89 ± 0.150.83 ± 0.151.91 ± 0.31
SMBG< 50 mg/dl, nocturnal0.20 ± 0.060.18 ± 0.060.27 ± 0.09
SMBG< 50 mg/dl with symptoms, nocturnal0.10 ± 0.040.09 ± 0.040.18 ± 0.07
SMBG< 36 mg/dl0.15 ± 0.030.10 ± 0.030.23 ± 0.05
Severe hypoglycemias0.17 ± 0.050.10 ± 0.030.17 ± 0.05
Serious hypoglycemiasNA ± NANA ± NANA ± NA

Adverse events

Collected over All Adverse Events (AE) regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lantus/Apidra-3—22/194 (11.3%)140/194 (72.2%)
Lantus/Apidra-1—23/194 (11.9%)150/194 (77.3%)
Novolog Mix 70/30—21/194 (10.8%)152/194 (78.4%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventLantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30
Angina pectorisCardiac disorders1/1943/1942/194
Hypoglycaemic unconsciousnessMetabolism and nutrition disorders1/1940/1943/194
Acute myocardial infarctionCardiac disorders2/1941/1940/194
Angina unstableCardiac disorders1/1942/1940/194
Urinary tract infectionInfections and infestations0/1942/1940/194
HypoglycaemiaMetabolism and nutrition disorders2/1941/1941/194
Renal failure acuteRenal and urinary disorders2/1940/1940/194
Acute coronary syndromeCardiac disorders0/1941/1940/194
Atrial fibrillationCardiac disorders1/1940/1940/194
Coronary artery occlusionCardiac disorders1/1941/1940/194
Most frequent other events
Showing 10 of 17
Most frequent other events
EventLantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30
Any infections and infestationsInfections and infestations66/19482/19490/194
Any musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders45/19444/19440/194
Any nervous system disordersNervous system disorders39/19429/19427/194
Any gastrointestinal disordersGastrointestinal disorders33/19432/19430/194
Any general disorders and administration site conditionsGeneral disorders21/19428/19425/194
Any respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders19/19427/19423/194
Upper respiratory tract infectionInfections and infestations18/19420/19425/194
SinusitisInfections and infestations6/19419/19416/194
NasopharyngitisInfections and infestations15/19417/1948/194
Oedema peripheralGeneral disorders14/19411/19410/194

Baseline characteristics

Age Continuous
Age Continuous(years)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
Mean54.9 ± 10.5453.7 ± 9.1153.7 ± 10.6554.1 ± 10.12
Sex: Female, Male
Sex: Female, Male(Participants)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
Female788886252
Male117108111336
Region of Enrollment
Region of Enrollment(participants)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
United States195196197588
Weight
Weight(kilograms (kg))Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
Mean95.2 ± 19.2197.2 ± 20.8897.9 ± 20.4996.8 ± 20.21
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilogram/m^2)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
Mean32.7 ± 5.7933.4 ± 6.0033.4 ± 5.6233.1 ± 5.80
Duration of diabetes at study entry
Duration of diabetes at study entry(years)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
Mean9.4 ± 6.809.1 ± 5.709.5 ± 5.879.3 ± 6.13
Age at onset of diabetes
Age at onset of diabetes(years)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
Mean46.0 ± 10.7445.1 ± 9.3644.8 ± 10.0145.3 ± 10.05
Oral antidiabetic treatment combination at study entry
Oral antidiabetic treatment combination at study entry(participants)Lantus/Apidra-3Lantus/Apidra-1Novolog Mix 70/30Total
sulfonylurea (SU) or meglitinide plus metformin979997293
SU or meglitinide plus thiazolinedione (TZD)991028
TZD plus metformin26272780
SU or meglitinide plus metformin plus TZD636163187
08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
09

References and documents

Publications

  • Polonsky WH, Thompson S, Wei W, Riddle MC, Chaudhari S, Jackson J, Bruno AS. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study. Diabetes Obes Metab. 2014 Nov;16(11):1121-7. doi: 10.1111/dom.12328. Epub 2014 Jul 12. PubMed 24919603 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2006
First posted
Oct 4, 2006
Start
May 2006
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Apr 26, 2011
Last update
May 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00384085
Lead sponsor
Sanofi
First posted
Oct 4, 2006
Start date
May 2006
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Apr 26, 2011
Last update
May 6, 2011

Study contacts

Medical Affairs
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin glulisine · Insulin Glargine

Start the discussion